Medicare AdvantageCoverageMedium impact
MA08.009w, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Neurology, Hematology +2 more·Medical Policy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.009w for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) has been reissued with an effective date of December 10, 2025. This is a policy reissue that may contain updated coverage criteria, prior authorization requirements, or billing guidelines for immunoglobulin therapies.
Action Required
By December 10, 2025: Billing team must review the complete updated policy MA08.009w for any changes to coverage criteria, prior authorization requirements, or documentation requirements for IVIG and SCIG treatments. Update billing workflows and provider documentation templates accordingly to ensure compliance with the reissued policy.